## Bakhtiar Yamini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4713064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	p52 signaling promotes cellular senescence. Cell and Bioscience, 2022, 12, 43.	4.8	4
2	Cerebrospinal fluid hydrocephalus shunting: cisterna magna, ventricular frontal, ventricular occipital. Neurosurgical Review, 2022, 45, 2615-2638.	2.4	6
3	CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. Scientific Reports, 2021, 11, 5665.	3.3	14
4	An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma. Cancers, 2021, 13, 1953.	3.7	26
5	Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105996.	1.6	3
6	p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nature Communications, 2020, 11, 5007.	12.8	8
7	DDX39B interacts with the pattern recognition receptor pathway to inhibit NF- $\hat{I}^{0}$ B and sensitize to alkylating chemotherapy. BMC Biology, 2020, 18, 32.	3.8	16
8	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Science Translational Medicine, 2019, 11, .	12.4	170
9	Primary Sellar Paraganglioma: Case Report with Literature Review and Immunohistochemistry Resource. World Neurosurgery, 2019, 125, 32-36.	1.3	8
10	Temozolomide Treatment Induces IncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. Cancer Research, 2019, 79, 2536-2548.	0.9	71
11	Intracranial hemorrhage as initial manifestation of plasma cell myeloma: A case report. Journal of Clinical Neuroscience, 2018, 50, 133-135.	1.5	1
12	NF-κB, Mesenchymal Differentiation and Glioblastoma. Cells, 2018, 7, 125.	4.1	44
13	Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors. World Neurosurgery, 2018, 117, e698-e704.	1.3	33
14	<i>BCL3</i> expression promotes resistance to alkylating chemotherapy in gliomas. Science Translational Medicine, 2018, 10, .	12.4	52
15	Nuclear factor-l <sup>°</sup> B in glioblastoma: insights into regulators and targeted therapy. Neuro-Oncology, 2016, 18, 329-339.	1.2	103
16	Nfkb1 suppresses DNA alkylation-induced tumor formation. Molecular and Cellular Oncology, 2015, 2, e968073.	0.7	2
17	S-phase-dependent p50/NF-DºB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability. Cell Cycle, 2015, 14, 566-576.	2.6	14
18	Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide. Cancer Research, 2015, 75, 2039-2048.	0.9	15

Bakhtiar Yamini

#	Article	IF	CITATIONS
19	Nfkb1/p50 and mammalian aging. Oncotarget, 2015, 6, 3471-3472.	1.8	1
20	Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 149-157.	3.3	83
21	Loss of Nfkb1 leads to early onset aging. Aging, 2014, 6, 931-942.	3.1	78
22	DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF-κB p50 and a single nucleotide in the κB-site. Nucleic Acids Research, 2013, 41, 764-774.	14.5	153
23	p50 (NF-κB1) Is an Effector Protein in the Cytotoxic Response to DNA Methylation Damage. Molecular Cell, 2011, 44, 785-796.	9.7	49
24	Convection-enhanced delivery for treatment of brain tumors. Expert Review of Anticancer Therapy, 2007, 7, S79-S85.	2.4	23
25	Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves <i>O</i> 6-Methylguanine–Induced Inhibition of p65 DNA Binding. Cancer Research, 2007, 67, 6889-6898.	0.9	36
26	Adenovirally Delivered Tumor Necrosis Factor-α Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy. Clinical Cancer Research, 2007, 13, 6217-6223.	7.0	31
27	Chemoinducible gene therapy. Anti-Cancer Drugs, 2005, 16, 1053-1058.	1.4	5
28	Surgery for low-grade gliomas: current evidence and controversies. Expert Review of Neurotherapeutics, 2005, 5, 13-19.	2.8	1
29	Initial endoscopic management of pineal region tumors and associated hydrocephalus: clinical series and literature review. Journal of Neurosurgery: Pediatrics, 2004, 100, 437-441.	1.3	68
30	Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor α by Temozolomide in Experimental Glioblastoma. Cancer Research, 2004, 64, 6381-6384.	0.9	45
31	Endoscopic Approach to Noncommunicating Fluid Spaces in the Shunted Patient. Pediatric Neurosurgery, 1999, 31, 237-241.	0.7	8
32	MIB-1 Proliferation Index Predicts Survival among Patients with Grade II Astrocytoma. Journal of Neuropathology and Experimental Neurology, 1998, 57, 931-936.	1.7	47